TP53 and cancer: The success, or otherwise, of drug interventions to reduce cancer incidence in LFS rests in part on developing further our understanding of the process of carcinogenesis in LFS and exploring how aberrant p53 activity interacts with host factors to facilitate the development of malignancy.